These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 30589994)

  • 1. Pharmacokinetics, pharmacodynamics, tolerability and prediction of clinically effective dose of ACT-774312: A novel CRTH2 antagonist.
    Géhin M; Lott D; Farine H; Issac M; Strasser D; Sidharta P; Dingemanse J
    Basic Clin Pharmacol Toxicol; 2019 Jun; 124(6):711-721. PubMed ID: 30589994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel CRTH2 antagonist: Single- and multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ACT-453859 in healthy subjects.
    Géhin M; Strasser DS; Zisowsky J; Farine H; Groenen PM; Dingemanse J; Sidharta PN
    J Clin Pharmacol; 2015 Jul; 55(7):787-97. PubMed ID: 25655470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
    Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
    J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single- and multiple-dose tolerability and pharmacokinetics of the CRTH2 antagonist setipiprant in healthy male subjects.
    Sidharta PN; Diamant Z; Dingemanse J
    Fundam Clin Pharmacol; 2014 Dec; 28(6):690-9. PubMed ID: 24734908
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic/Pharmacodynamic Modelling of Receptor Internalization with CRTH2 Antagonists to Optimize Dose Selection.
    Krause A; Zisowsky J; Strasser DS; Gehin M; Sidharta PN; Groenen PMA; Dingemanse J
    Clin Pharmacokinet; 2016 Jul; 55(7):813-821. PubMed ID: 26692193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics, Safety, and Tolerability of Fevipiprant (QAW039), a Novel CRTh2 Receptor Antagonist: Results From 2 Randomized, Phase 1, Placebo-Controlled Studies in Healthy Volunteers.
    Erpenbeck VJ; Vets E; Gheyle L; Osuntokun W; Larbig M; Neelakantham S; Sandham D; Dubois G; Elbast W; Goldsmith P; Weiss M
    Clin Pharmacol Drug Dev; 2016 Jul; 5(4):306-13. PubMed ID: 27310331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis.
    Krug N; Gupta A; Badorrek P; Koenen R; Mueller M; Pivovarova A; Hilbert J; Wetzel K; Hohlfeld JM; Wood C
    J Allergy Clin Immunol; 2014 Feb; 133(2):414-9. PubMed ID: 24332218
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Setipiprant, a selective CRTH2 antagonist, reduces allergen-induced airway responses in allergic asthmatics.
    Diamant Z; Sidharta PN; Singh D; O'Connor BJ; Zuiker R; Leaker BR; Silkey M; Dingemanse J
    Clin Exp Allergy; 2014 Aug; 44(8):1044-52. PubMed ID: 24964348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacological characterization of CRTh2 antagonist LAS191859: Long receptor residence time translates into long-lasting in vivo efficacy.
    Calbet M; Andrés M; Armengol C; Bravo M; Eichhorn P; López R; García-González V; Roberts R; Miralpeix M
    Pharmacol Res; 2016 Sep; 111():208-216. PubMed ID: 27317944
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, tolerability, pharmacokinetics, and pharmacodynamics of fimasartan following single and repeated oral administration in the fasted and fed states in healthy subjects.
    Chi YH; Lee H; Paik SH; Lee JH; Yoo BW; Kim JH; Tan HK; Kim SL
    Am J Cardiovasc Drugs; 2011 Oct; 11(5):335-46. PubMed ID: 21910510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized study of BI 671800, a CRTH2 antagonist, as add-on therapy in poorly controlled asthma.
    Miller D; Wood C; Bateman E; LaForce C; Blatchford J; Hilbert J; Gupta A; Fowler A
    Allergy Asthma Proc; 2017 Mar; 38(2):157-164. PubMed ID: 28234053
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: a dose-block-randomized, double-blind, placebo-controlled, ascending single-dose, Phase I study.
    Lim KS; Kim JR; Choi YJ; Shin KH; Kim KP; Hong JH; Cho JY; Shin HS; Yu KS; Shin SG; Kwon OH; Hwang DM; Kim JA; Jang IJ
    Clin Ther; 2008 Oct; 30(10):1817-30. PubMed ID: 19014837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two Phase II randomized trials on the CRTh2 antagonist AZD1981 in adults with asthma.
    Kuna P; Bjermer L; Tornling G
    Drug Des Devel Ther; 2016; 10():2759-70. PubMed ID: 27621597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heightened response of eosinophilic asthmatic patients to the CRTH2 antagonist OC000459.
    Pettipher R; Hunter MG; Perkins CM; Collins LP; Lewis T; Baillet M; Steiner J; Bell J; Payton MA
    Allergy; 2014 Sep; 69(9):1223-32. PubMed ID: 24866478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, pharmacodynamics, and safety of a prostaglandin D2 receptor antagonist.
    Lai E; Wenning LA; Crumley TM; De Lepeleire I; Liu F; de Hoon JN; Van Hecken A; Depré M; Hilliard D; Greenberg H; O'Neill G; Metters K; Gottesdiener KG; Wagner JA
    Clin Pharmacol Ther; 2008 Jun; 83(6):840-7. PubMed ID: 17882161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacology of single- and multiple-ascending doses of ACT-178882, a new direct renin inhibitor, and its pharmacokinetic interaction with food and midazolam.
    Dingemanse J; Nicolas L; Binkert C
    Fundam Clin Pharmacol; 2013 Dec; 27(6):698-710. PubMed ID: 22849770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The oral CRTh2 antagonist QAW039 (fevipiprant): A phase II study in uncontrolled allergic asthma.
    Erpenbeck VJ; Popov TA; Miller D; Weinstein SF; Spector S; Magnusson B; Osuntokun W; Goldsmith P; Weiss M; Beier J
    Pulm Pharmacol Ther; 2016 Aug; 39():54-63. PubMed ID: 27354118
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, pharmacokinetics, and pharmacodynamics of CHF 3381, a novel N-methyl-D-aspartate antagonist, after single oral doses in healthy subjects.
    Tarral A; Dostert P; Guillevic Y; Fabbri L; Rondelli I; Mariotti F; Imbimbo BP
    J Clin Pharmacol; 2003 Aug; 43(8):901-11. PubMed ID: 12953347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers.
    Vaughan D; Speed J; Medve R; Andrews JS
    Clin Ther; 2010 Jan; 32(1):146-60. PubMed ID: 20171420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker.
    Huynh C; Henrich A; Strasser DS; Boof ML; Al-Ibrahim M; Meyer Zu Schwabedissen HE; Dingemanse J; Ufer M
    Clin Pharmacol Ther; 2021 Jun; 109(6):1648-1659. PubMed ID: 33406277
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.